CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.60 USD
-0.03 (-0.38%)
Updated Jul 26, 2024 03:59 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CASI 6.60 -0.03(-0.38%)
Will CASI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Other News for CASI
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals Freezes Juventas Assets Amid Dispute
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
Biotech Alert: Searches spiking for these stocks today
CASI Pharmaceuticals Secures $15M in Funding